Cerebro-rhino-orbital mucormycosis and aspergillosis coinfection in a patient with diabetes mellitus: A case report

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Johan Maertens, Issam Raad, Kieren A. Marr et al. · The Lancet · 2015 · 938 citations

Antifungal Agent, Isavuconazole Versus Voriconazole, Antifungal Agents +7

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

Francisco M. Marty, Luis Ostrosky‐Zeichner, Oliver A. Cornely et al. · The Lancet Infectious Diseases · 2016 · 676 citations

Single-arm Open-label Trial, Antifungal Agent, Antifungal Agents +4

Fungal infections of the central nervous system and paranasal sinuses in onco‐haematologic patients. Epidemiological study reporting the diagnostic‐therapeutic approach and outcome in 89 cases

Anna Candoni, Alessandro Busca, Roberta Di Blasi et al. · Mycoses · 2018 · 75 citations · Full text

Diagnostic Mycology, Immunodeficiencies, Pathology +18

Rhino-orbital-cerebral mucormycosis and aspergillosis: differential diagnosis and treatment

Susan Arndt, Antje Aschendorff, Matthias Echternach et al. · European Archives of Oto-Rhino-Laryngology · 2008 · 72 citations

Diagnostic Mycology, Rhino-orbital-cerebral Mucormycosis, Fungal Pathogen +1

Distribution of invasive fungal infections: Molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: A 3-year experience with 490 patients under intensive care

Zeinab Borjian Boroujeni, Sina Shamsaei, Mohammad Yarahmadi et al. · Microbial Pathogenesis · 2020 · 64 citations

Diagnostic Mycology, Molecular Epidemiology, Antifungal Agents +5